Cargando…

Shenling Baizhu San supresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration

BACKGROUND: Shenling Baizhu San (SBS) is a well-known and classical Chinese medicine formula. It has been used for treatment of gastrointestinal disorders for about nine hundred years. Recent reports showed that it was effective in curing colitis and ameliorating the major manifestations of postoper...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Xiaochang, Xu, Wenjuan, Shao, Meng, Fan, Qin, Wen, Ge, Li, Changke, Jing, Linlin, Sun, Xuegang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428101/
https://www.ncbi.nlm.nih.gov/pubmed/25897964
http://dx.doi.org/10.1186/s12906-015-0649-9
_version_ 1782370839033806848
author Lin, Xiaochang
Xu, Wenjuan
Shao, Meng
Fan, Qin
Wen, Ge
Li, Changke
Jing, Linlin
Sun, Xuegang
author_facet Lin, Xiaochang
Xu, Wenjuan
Shao, Meng
Fan, Qin
Wen, Ge
Li, Changke
Jing, Linlin
Sun, Xuegang
author_sort Lin, Xiaochang
collection PubMed
description BACKGROUND: Shenling Baizhu San (SBS) is a well-known and classical Chinese medicine formula. It has been used for treatment of gastrointestinal disorders for about nine hundred years. Recent reports showed that it was effective in curing colitis and ameliorating the major manifestations of postoperational colorectal cancer (CRC). This study was to evaluate the effects of SBS on azoxymethane (AOM) and dextran sodium sulfate (DSS) induced colitis associated CRC (caCRC) and to analyze the underlying mechanism of SBS in preventing CRC. METHODS: The colon tissue of mice in different group was determined by immunohistochemistry and western blot. TGF-β1 in serum was measured by ELISA. Myeloid-derived suppressor cells (MDSCs) were identified by flow cytometry and immunohistochemistry. RESULTS: The formed neoplasms phenotypically resembled human caCRC with upregulated β-catenin, p53 and proliferating cell nuclear antigen (PCNA). SBS treatment reduced the death rate of mice and decreased the incidence and multiplicity of colonic neoplasms. SBS decreased the number of MDSCs and the level of transforming growth factor β1 (TGF-β1). SBS alleviated epithelial mesenchymal transition (EMT) through downregulating N-cadherin (N-cad), Vimentin, Fibronectin, Snail, and upregulating E-cadherin (E-cad). It reduced the activation of Wnt5a and EMT induced by TGF-β1. CONCLUSIONS: SBS reduced the death rate through decreasing the incidence and multiplicity of colonic tumors. SBS lowered MDSCs infiltration and inhibited TGF-β1 induced EMT to exert its anti-caCRC effects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12906-015-0649-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4428101
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44281012015-05-13 Shenling Baizhu San supresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration Lin, Xiaochang Xu, Wenjuan Shao, Meng Fan, Qin Wen, Ge Li, Changke Jing, Linlin Sun, Xuegang BMC Complement Altern Med Research Article BACKGROUND: Shenling Baizhu San (SBS) is a well-known and classical Chinese medicine formula. It has been used for treatment of gastrointestinal disorders for about nine hundred years. Recent reports showed that it was effective in curing colitis and ameliorating the major manifestations of postoperational colorectal cancer (CRC). This study was to evaluate the effects of SBS on azoxymethane (AOM) and dextran sodium sulfate (DSS) induced colitis associated CRC (caCRC) and to analyze the underlying mechanism of SBS in preventing CRC. METHODS: The colon tissue of mice in different group was determined by immunohistochemistry and western blot. TGF-β1 in serum was measured by ELISA. Myeloid-derived suppressor cells (MDSCs) were identified by flow cytometry and immunohistochemistry. RESULTS: The formed neoplasms phenotypically resembled human caCRC with upregulated β-catenin, p53 and proliferating cell nuclear antigen (PCNA). SBS treatment reduced the death rate of mice and decreased the incidence and multiplicity of colonic neoplasms. SBS decreased the number of MDSCs and the level of transforming growth factor β1 (TGF-β1). SBS alleviated epithelial mesenchymal transition (EMT) through downregulating N-cadherin (N-cad), Vimentin, Fibronectin, Snail, and upregulating E-cadherin (E-cad). It reduced the activation of Wnt5a and EMT induced by TGF-β1. CONCLUSIONS: SBS reduced the death rate through decreasing the incidence and multiplicity of colonic tumors. SBS lowered MDSCs infiltration and inhibited TGF-β1 induced EMT to exert its anti-caCRC effects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12906-015-0649-9) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-22 /pmc/articles/PMC4428101/ /pubmed/25897964 http://dx.doi.org/10.1186/s12906-015-0649-9 Text en © Lin et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lin, Xiaochang
Xu, Wenjuan
Shao, Meng
Fan, Qin
Wen, Ge
Li, Changke
Jing, Linlin
Sun, Xuegang
Shenling Baizhu San supresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration
title Shenling Baizhu San supresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration
title_full Shenling Baizhu San supresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration
title_fullStr Shenling Baizhu San supresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration
title_full_unstemmed Shenling Baizhu San supresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration
title_short Shenling Baizhu San supresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration
title_sort shenling baizhu san supresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428101/
https://www.ncbi.nlm.nih.gov/pubmed/25897964
http://dx.doi.org/10.1186/s12906-015-0649-9
work_keys_str_mv AT linxiaochang shenlingbaizhusansupressescolitisassociatedcolorectalcancerthroughinhibitionofepithelialmesenchymaltransitionandmyeloidderivedsuppressorinfiltration
AT xuwenjuan shenlingbaizhusansupressescolitisassociatedcolorectalcancerthroughinhibitionofepithelialmesenchymaltransitionandmyeloidderivedsuppressorinfiltration
AT shaomeng shenlingbaizhusansupressescolitisassociatedcolorectalcancerthroughinhibitionofepithelialmesenchymaltransitionandmyeloidderivedsuppressorinfiltration
AT fanqin shenlingbaizhusansupressescolitisassociatedcolorectalcancerthroughinhibitionofepithelialmesenchymaltransitionandmyeloidderivedsuppressorinfiltration
AT wenge shenlingbaizhusansupressescolitisassociatedcolorectalcancerthroughinhibitionofepithelialmesenchymaltransitionandmyeloidderivedsuppressorinfiltration
AT lichangke shenlingbaizhusansupressescolitisassociatedcolorectalcancerthroughinhibitionofepithelialmesenchymaltransitionandmyeloidderivedsuppressorinfiltration
AT jinglinlin shenlingbaizhusansupressescolitisassociatedcolorectalcancerthroughinhibitionofepithelialmesenchymaltransitionandmyeloidderivedsuppressorinfiltration
AT sunxuegang shenlingbaizhusansupressescolitisassociatedcolorectalcancerthroughinhibitionofepithelialmesenchymaltransitionandmyeloidderivedsuppressorinfiltration